for people ages 18 years and up (full criteria)
study started
estimated completion
Principal Investigator
by Zev Wainberg, MD (ucla)



This randomized phase 1b/2 open-label study will evaluate the antitumour activity and safety of etrumadenant (AB928) treatment combinations in participants with metastatic colorectal cancer.

Official Title

A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating The Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer


This is a multicenter, open-label Phase 1b/2 study in participants with metastatic colorectal cancer that will assess the antitumour activity and safety of etrumadenant. Approximately 250 participants will be enrolled to 1 of 3 cohorts: Cohort A) etrumadenant + zimberelimab +mFOLFOX-6 +/-bevacizumab vs mFOLFOX-6 +/-bevacizumab Cohort B) etrumadenant + zimberelimab +mFOLFOX-6 +/-bevacizumab vs regorafenib Cohort C) chemotherapy-free combinations of etrumadenant + zimberelimab + other agents The primary objective of this clinical study is to evaluate the safety of etrumadenant-based combination therapy in participants with metastatic colorectal cancer.


Metastatic Colorectal Cancer mCRC Colorectal Neoplasms Bevacizumab etrumadenant zimberelimab mFOLFOX-6 regimen regorafenib etrumadent+ zimberelimab + AB680


You can join if…

Open to people ages 18 years and up

  • Male and female participants ≥ 18 years of age
  • Histologically confirmed metastatic colorectal adenocarcinoma
  • Must have at least 1 measurable lesion per RECIST v1.1
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Life expectancy at least 3 months
  • Adequate hematologic and end-organ function
  • Negative HIV, Hep B and Hep C antibody testing
  • Agreement to remain abstinent or use contraceptive measures with female partners of reproductive potential, and agreement to refrain from donating sperm, for 30 days after the last dose of etrumadenant, 90 days after the last dose of zim, 180 days after mFOLFOX-6 and 180 days after bev, whichever is longer.
  • Inclusion Criteria for Cohort A:
  • Disease progression following not more than one prior line of treatment for mCRC that consisted of oxaliplatin or irinotecan containing chemotherapy in combination with a biologic agent
  • Inclusion Criteria for Cohort B:
  • Disease progression during or following not more that two separate lines of treatment for mCRC that consisted of oxaliplatin, and irinotecan containing chemotherapy in combination with a biologic agent

You CAN'T join if...

  • Previous anticancer treatment within 4 weeks prior to initiation of study treatment
  • Prior allogeneic stem cell or solid organ transplant
  • Treatment with systemic immunostimulatory agents within 4 weeks prior to initiation of study treatment
  • Use of any live vaccines against infectious diseases within 28 days of first dose.
  • Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
  • Current treatment with anti-viral therapy for HBV
  • Structurally unstable bone lesions suggesting impending fracture
  • History or leptomeningeal disease
  • History of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan
  • History of malignancy other than colorectal cancer within 2 years prior to screening, except for malignancies such as non-melanoma skin carcinoma or ductal carcinoma in situ
  • Active tuberculosis
  • Treatment with therapeutic oral or intravenous (IV) antibiotics within 2 weeks prior to initiating study treatment
  • Severe infection within 4 weeks (28 days) prior to initiation of study treatment
  • Significant cardiovascular disease, unstable or new onset of angina within 3 months prior to initiation of treatment, or myocardial infarction within 6 months prior to study treatment or unstable arrhythmia
  • Major surgical procedures, other than for diagnosis, within 4 weeks prior to initiation of study treatment, or anticipation of need for major surgical procedure during the study
  • Known allergy or hypersensitivity to any of the study drugs or their excipients
  • Inability to swallow medications
  • Malabsorption condition that would alter the absorption of orally administered medications
  • Evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding (i.e., in the absence of therapeutic anticoagulation)
  • Prior treatment with an agent targeting the adenosine pathway
  • Active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain Barré syndrome, or multiple sclerosis
  • Exclusion Criteria for Cohorts A and B:
  • Prior treatment with immune checkpoint blockade therapies including anit-cytotoxic T lymphocyte-associated protein-4, anti PD-1, and anti-PD-L1 therapeutic antibodies
  • Mutation in the BRAF oncogene. Patients with unknown BRAF status will be required to undergo testing at a local laboratory and provide results at screening


  • UCLA Hematology Oncology accepting new patients
    Santa Monica California 90404 United States
  • City of Hope Comprehensive Cancer Center accepting new patients
    Duarte California 91010 United States

Lead Scientist at UC Cancer

  • Zev Wainberg, MD (ucla)
    HS Clinical Professor, Medicine. Authored (or co-authored) 108 research publications


accepting new patients
Start Date
Completion Date
Arcus Biosciences, Inc.
Phase 1/2 Colorectal Cancer Research Study
Study Type
Expecting 247 study participants
Last Updated